Should You Buy, Sell, or Hold McKesson Before Q3 Earnings?

Core Insights - McKesson Corporation (MCK) is set to report its third-quarter fiscal 2026 results on February 4, with sales expected to reach $105.54 billion, indicating a year-over-year growth of 10.8% [1][7] - The projected earnings per share (EPS) is $9.31, reflecting a growth of 15.9% [1][7] - The company has shown an earnings surprise of 10.54% in the last quarter, beating estimates in three of the last four quarters with an average surprise of 3.49% [2] Earnings Prediction Model - The Zacks model does not predict a definitive earnings beat for McKesson this quarter, as the Earnings ESP is 0.00% and the company holds a Zacks Rank of 3 (Hold) [3][4] Factors Influencing Q3 Performance - McKesson's third-quarter performance is expected to be strong, driven by growth in specialty distribution, oncology services, and prescription technology solutions [5][7] - Revenue growth is anticipated from increased prescription volumes and the expansion of GLP-1 medications, although margin performance will be closely monitored [5][8] - Operating profit is likely to exceed revenue growth due to a favorable business mix and efficiency initiatives [8] Segment Performance - The North American Pharmaceutical segment is expected to show steady growth, supported by increased prescription volumes and specialty product momentum, particularly from GLP-1 medications [9] - The Oncology and Multispecialty segment is projected to be a standout performer, benefiting from organic growth and contributions from recent acquisitions [10][11] - Revenue growth in Prescription Technology Solutions is expected to be driven by higher prescription volumes and demand for affordability solutions, although increased investment spending may impact near-term profit growth [12] - The Medical-Surgical Solutions segment may reflect a modest drag on overall growth due to lower demand for vaccines and testing products [13] Stock Performance - McKesson's shares have increased by 19.1% over the past six months, outperforming the industry growth of 15.7% and the S&P 500 Index growth of 12.4% [14] Conclusion - Strong momentum in higher-growth platforms and efficiency gains provide earnings stability, but near-term variability from investment spending and mix shifts limits visibility for further upside [15]